Fibroblast growth factor 1 - CardioVascular BioTherapeutics

Drug Profile

Fibroblast growth factor 1 - CardioVascular BioTherapeutics

Alternative Names: Acidic FGF; Cardio Vascu-Grow; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141)

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CardioVascular BioTherapeutics Inc
  • Class Anti-ischaemics; Fibroblast growth factors
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Diabetic foot ulcer; Wounds
  • No development reported Peripheral vascular disorders
  • Discontinued Back pain; Diabetes mellitus; Ischaemia; Osteoporosis; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Peripheral-vascular-disorders in USA (IM, Injection)
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
  • 29 Apr 2014 CardioVascular BioTherapeutics suspends a phase II trial in Coronary disorders in USA (NCT00117936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top